Every material Form 8-K Northrop Grumman filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Northrop Grumman reported third quarter 2026 sales of $11.1 billion, up 7% from $10.4 billion a year earlier, and diluted earnings per share of $7.89 versus $7.67. The company raised its 2026 guidance for sales, segment operating income and MTM-adjusted EPS, while operating margin rate declined to 11.4% from 11.9%.
Q3 2026 sales rose 7% to $11.1 billion; net earnings were $1.1 billion, or $7.89 per diluted share, versus $7.67 a year earlier
2026 MTM-adjusted EPS guidance raised to $29.35 to $29.75 from $28.60 to $29.10; sales guidance is $43.75 billion to $44.25 billion
Backlog reached $109.6 billion at September 30, 2026, up 15% from $95.7 billion at December 31, 2025; net awards were $16.4 billion in the quarter
Northrop Grumman's independent directors approved a one-time performance-based equity grant to Chair, CEO and President Kathy J. Warden on August 19, 2026. The award pays out based on the company's absolute stock price change through December 31, 2031, and is tied to her continued service, which links her pay directly to shareholder returns.
Award approved by independent directors on August 19, 2026; disclosed in an 8-K dated August 21, 2026
Target award is 35,910 Market Stock Units (MSUs), with payout ranging from 0% to 150% of target
Performance period ends December 31, 2031; full target payout requires at least 10% stock price appreciation
Payout is 0% if the stock falls more than 25% and 150% if it rises 50% or more
Northrop Grumman reported second quarter 2026 sales of $10.9 billion, up 5% from a year earlier, and a record backlog of $105 billion. Diluted EPS fell to $7.68 from $8.15 because the prior-year quarter included a $231 million gain on the training services divestiture, and the company raised its 2026 sales and MTM-adjusted EPS guidance.
Q2 2026 sales were $10.9 billion, up 5% from $10.4 billion in Q2 2025.
Diluted EPS was $7.68 versus $8.15; net earnings were $1.1 billion versus $1.2 billion.
2026 sales guidance raised to $43.75 billion to $44.25 billion; MTM-adjusted EPS guidance raised to $28.60 to $29.10, an increase of $1.20.
Backlog reached a company record of $105 billion after $20 billion in net awards in the quarter.
Northrop Grumman reported first-quarter 2026 sales of $9.9 billion, up 4% from $9.5 billion a year earlier, and diluted earnings per share of $6.14 versus $3.32. The gain was largely due to the absence of a $477 million B-21 loss provision recorded in the prior-year quarter, and the company reaffirmed its 2026 financial guidance. Shareholders get a clear improvement in the headline measures, though first-quarter free cash flow was negative $1.8 billion.
Sales rose 4% to $9.9 billion; organic sales rose 5% to $9.9 billion from $9.4 billion
Diluted EPS was $6.14 versus $3.32; net earnings were $875 million versus $481 million
Operating margin rate was 10.0% versus 6.1%, driven by the absence of the prior-year $477 million B-21 loss provision
2026 guidance reaffirmed as of April 21, 2026: sales $43.5 billion to $44.0 billion and MTM-adjusted EPS $27.40 to $27.90
Northrop Grumman's board elected Admiral Christopher W. Grady, a retired Vice Chairman of the Joint Chiefs of Staff, to the board effective February 12, 2026, expanding the board from 12 to 13 members. The filing also sets the 2026 executive incentive metrics and names James S. Turley as Lead Independent Director effective May 20, 2026, which is a governance change rather than a financial result.
Admiral Christopher W. Grady elected to the board effective February 12, 2026; board size increased from 12 to 13 members
Grady receives a $145,000 annual cash retainer, a $15,000 retainer for Audit and Risk Committee service, and a $182,500 annual deferred stock unit grant
James S. Turley to become Lead Independent Director effective May 20, 2026, succeeding Madeleine A. Kleiner, who retires at the 2026 Annual Meeting
2026 incentive plan weights cash flow from operations 20%, segment operating income 25%, sales 25% and strategic metrics 30%
Northrop Grumman reported fourth-quarter 2025 sales up 10% to $11.7 billion and full-year 2025 sales of $42.0 billion, with full-year MTM-adjusted EPS of $26.34 versus $26.08 in 2024. The company guided 2026 sales of $43.5 billion to $44.0 billion and MTM-adjusted EPS of $27.40 to $27.90, consistent with its October outlook, and reported a record backlog of $95.7 billion.
Q4 2025 sales rose to $11.7 billion from $10.7 billion; full-year sales were $42.0 billion, up 2%
Full-year 2025 diluted EPS was $29.08, including a $394 million after-tax mark-to-market pension benefit; MTM-adjusted EPS was $26.34
2026 guidance: sales of $43.5 billion to $44.0 billion, MTM-adjusted EPS of $27.40 to $27.90, and free cash flow of $3.1 billion to $3.5 billion
Full-year 2025 segment operating income fell 4%, mainly due to a $477 million B-21 loss provision in the first quarter
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Northrop Grumman filing is on SEC EDGAR ↗. 8-K briefs of other companies →